pharma news

News

Bayer's asundexian starts EU review for ischaemic stroke

The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

News

Lilly wins new FDA approval for eczema drug Ebglyss

Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.

News

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

News

Stop sign with green fields in the background

Sanofi abandons phase 3 trial of neurology drug riliprubart

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

News

Moderna Innovation and Technology Centre

Moderna jab on trial for cancer-causing syndrome

Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.

Bayer's asundexian starts EU review for ischaemic stroke

Lilly wins new FDA approval for eczema drug Ebglyss

AbbVie's migraine drug cleared for migraine attacks on NHS

Cancer biotech Parabilis books record IPO, raising $670m

Sanofi abandons phase 3 trial of neurology drug riliprubart

Moderna jab on trial for cancer-causing syndrome

Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ...

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks